Sign in
CompletedPhase 2/3

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

Key facts

Who runs it
Neurocentria, Inc.
Where
Berlin, Boston, Garden Grove, Lakeland, Las Vegas, Maitland, Meridian, Miami, and North Charleston, United StatesSee the 9 sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
223 people enrolled
Started
25 Feb 2023
Ended
17 Jan 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • NRCT-101-SR
  • Placebo
Record updated
3 June 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Male or female, ≥ 18 years of age at screening
  • Has a primary diagnosis of ADHD according to the Diagnostic and Statistical Manual, Fifth Edition (DSM-5) classification, confirmed with Mini International Neuropsychiatric Interview (MINI) using DSM-5 probes
  • AISRS ≥ 26 at screening and baseline, and does not change by more than 25% from screening to baseline, except subjects who stop taking ADHD medication after screening may have an increase of more than 25%
  • Has a minimum score of 4 on the CGI-S at baseline
  • Must be fluent in English, and capable of reading, writing, and communicating effectively with others and willing to participate in laboratory classroom
  • Completion of at least 10 years of formal education
  • Hearing and Vision ability sufficient to complete cognitive testing, in investigator's opinion
  • Willing and able to give informed consent
  • Total Body weight (bw) must be ≥ 50 kg and ≤ 105 kg and lean body mass (LBM) must be ≤ 75 kg at screening
  • Naïve to stimulant or non-stimulant medications used for the treatment of ADHD or have discontinued stimulants at least 2 weeks and non-stimulants at least 3 weeks prior to randomization

Who cannot take part

  • Current abnormal thyroid function as defined as abnormal screening thyroid stimulating hormone. Treatment for at least 3 months with a stable dose of thyroid medication is permitted
  • Reproduction:; Females of childbearing potential (FOCP) must be either sexually inactive abstinent) or, if sexually active, must agree to use one of the following acceptable birth control methods beginning 30 days prior to the first dose of study drug and throughout the study: i. Simultaneous use of male condom and intra-uterine contraceptive device placed at least 4 weeks prior to first study drug administration ii. Surgically sterile male partner iii. Simultaneous use of male condom and diaphragm with spermicide iv. Established hormonal contraceptive b. Males must: i. Use 2 methods of contraception in combination if his female partner is of childbearing potential; this combination of contraceptive methods must be used from the Baseline Visit to ≥ 1 month after the last dose of study drug, or ii. Have been surgically sterilized prior to the Screening Visit
  • Is currently participating in another clinical trial or has participated in a clinical trial within 30 days prior to the Screening Visit
  • Has previously participated in a NRCT-101SR investigational study or a study that includes the active ingredient of NRCT-101SR
  • Changes in medications or doses of medication as follows:; All allowed concomitant medications, supplements, or other substances must be at stable doses for at least 30 days prior to screening and must be kept as stable as medically possible during the trial. For allowed concomitant medications, any dosing change within 30 days of Screening may be allowed if, in the opinion of the investigator, it will not affect or influence study results
  • Lifetime history of severe psychiatric symptoms of major depression requiring hospitalization, bipolar disorder, schizophrenia of schizoaffective disorder, hallucinations, or delusions. Severe comorbid disorders such as PTSD, severe obsessive-compulsive disorder, or other symptomatic presentation that, in the opinion of the examining physician, will contraindicate NRCT-101SR treatment or confound efficacy or safety assessments. Subjects with mild to moderate forms of social phobia or dysthymia, for instance, may be included
  • History of seizures (other than infantile febrile seizures), any tic disorder (except transient tic disorder and subject has no episodes for at least 1 year), or a current diagnosis of Tourette's Disorder
  • Recent history (within the past 1 year) of suspected substance abuse or dependence disorder (excluding stable nicotine use) in accordance with DSM-5 criteria. (Note: subject's average nicotine use should not be exceeded during each LC visit)
  • History of significant gastrointestinal disorders, such as chronic diarrhea, irritable bowel syndrome, ulcerative colitis, Crohn's disease, etc
  • Has history of severe drug allergy or hypersensitivity to the study medication or its excipients
  • Known history of symptomatic cardiac disease, advanced atherosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary heart disease, transient ischemic attack or stroke or other serious cardiac problems
  • Known family history of sudden cardiac death or ventricular arrhythmia
  • Serious or unstable clinically important systemic illness or disease that, in the judgment of the investigator, is likely to affect cognitive assessment, deteriorate, or affect the subject's safety or ability to complete the study, including hepatic (e.g., Child-Pugh grade C), renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, immunologic, infectious, or hematologic disorders
  • Hypermagnesemia; magnesium > 2.5 mg/dL
  • Subject is functioning below an age-appropriate level intellectually, as judged by the investigator
  • Poor kidney function; corrected estimated glomerular filtration rate (eGFRcorr) < 40 mL/min/m2
  • Female subjects who are pregnant and/or lactating
  • A "yes" answer to "suicidal ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the Columbia-Suicide Severity Rating Scale (C-SSRS) assessment at screening (in the past 12 months)
  • Currently living in an institutional facility such as a nursing home
  • Severe physical disability not associated with cognitive function that limits ability to complete testing (e.g., severe tremor, debilitating arthritis, etc.)
  • Investigators and their immediate family members are not permitted to participate in the study
  • Consumes more than a weekly average of: 2 drinks / day or more than 3 drinks in any day for males; 1 drink / day or more than 2 drinks in any day for females

Where in United States

  • Hassman Research InstituteBerlin, United States
  • Alcanza Clinical Research CompanyBoston, United States
  • Collaborative Neuroscience NetworkGarden Grove, United States
  • Lakeland, FloridaHospital not named in the registry
  • Center for Psychiatry and Behavioral MedicineLas Vegas, United States
  • Maitland, FloridaHospital not named in the registry
  • Velocity Clinical Research, MeridianMeridian, United States
  • Miami Dade Medical Research InstituteMiami, United States
  • Coastal Carolina Research Center - North CharlestonNorth Charleston, United States

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the efficacy and safety of NRCT-101SR compared to placebo in adult patients with ADHD aged 18 years and older.

The 2 groups in the trial

  • NRCT-101SRTreatment being tested

    Two-tiered fixed dose of 1,500 or 2,000 mg/day. Two NRCT-101SR tablets (375 mg or 500 mg based on lean body mass) by mouth twice daily

    Treatment: NRCT-101-SR

  • Matching PlaceboPlacebo, for comparison

    Two-tiered fixed dose of 1,500 or 2,000 mg/day. Two NRCT-101SR placebo tablets (375 mg or 500 mg based on lean body mass) by mouth twice daily

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder
Record updated
3 June 2025